Zobrazeno 1 - 3
of 3
pro vyhledávání: '"James Kissling"'
Autor:
C. James Kissling, Stephan Glund, Christian Friedrich, Dominick A. Lionetti, Hans-Juergen Woerle, Sanjay Patel, Julian Righetti, Silke Retlich, Ulrike Graefe-Mody
Publikováno v:
British Journal of Clinical Pharmacology. 76:445-454
Aim This was an open label, multicentre phase I trial to study the pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin in African American patients with type 2 diabetes mellitus (T2DM). Methods Forty-one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74a14e29f81bfd29e6e9215c7b22e78a
https://doi.org/10.1111/bcp.12077
https://doi.org/10.1111/bcp.12077
Publikováno v:
The Journal of Clinical Pharmacology. 49:1408-1416
IDX899 and IDX989 are new non-nucleoside reverse-transcriptase inhibitors (NNRTIs) that exhibit potent inhibition of HIV-1 replication, including NNRTI-resistant mutants. This microdose study investigates the pharmacokinetics and determined oral bioa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9326dc1dbc88e987152464fc46ca4b1
https://doi.org/10.1177/0091270009343698
https://doi.org/10.1177/0091270009343698
Autor:
Aram Oganesian, Gavin Choy, Amarpal Sahai, Scott Rasmussen, Mohammad Azab, Joanne Collier, James Kissling, Rajashree Joshi-Hangal, Gil Fine, Sanjeev Redkar
Publikováno v:
Cancer chemotherapy and pharmacology. 70(1)
Amuvatinib is a multi-targeted tyrosine kinase inhibitor with activity that also disrupts DNA damage repair through suppression of homologous recombination protein Rad51. Amuvatinib dry-powder capsules (DPC) showed evidence of activity in early Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34805c3da4ef5039150cb751e433cbde
https://pubmed.ncbi.nlm.nih.gov/22349808
https://pubmed.ncbi.nlm.nih.gov/22349808